by Suman Gupta
MUMBAI, NATIONAL, 05 AUGUST, 2026:Temasek and Motilal Oswal Group-backed Molbio Diagnostics has fixed the price band for its Rs 930.7-crore initial public offering (IPO) at Rs 768-807 per share. The public issue will open for subscription on August 10 and close on August 12, while the anchor investor book will open on August 7.
Investors can bid for a minimum of 18 equity shares and in multiples thereafter. At the upper end of the price band, the IPO is valued at Rs 930.7 crore. The issue comprises a fresh issue of shares worth Rs 200 crore and an offer for sale (OFS) of 91.66 lakh shares by existing shareholders.
The IPO will open alongside the Rs 3,067-crore Dhoot Transmission public issue, making it one of two mainboard IPOs scheduled to launch on August 10. The OFS includes shares being sold by promoters Exxora Trading and Dr Chandrasekhar Bhaskaran Nair, investor India Business Excellence Fund, and seven other shareholders.
Following the issue, the promoters’ stake will dilute from the current 46.65%, while the remaining 53.35% is held by investors, including Temasek Holdings-backed V Sciences Investments and Motilal Oswal Group’s India Business Excellence Fund.
Goa-based Molbio Diagnostics develops point-of-care (POC) diagnostic solutions. Its flagship Truenat platform, patented in more than 100 countries, enables rapid molecular testing for diseases such as tuberculosis (TB), COVID-19, Hepatitis B and C, Human Immunodeficiency Virus (HIV), and Human Papillomavirus (HPV).
The PCR-based platform is designed to deliver decentralised diagnostic results within an hour, particularly in resource-constrained settings.
The company plans to utilise Rs 105.5 crore from the fresh issue proceeds to establish a research and development facility and a Centre of Excellence through its wholly owned subsidiary, Bigtec, along with office infrastructure as told to our newsman Sachin Murdeshwar. Another Rs 72.2 crore will be used to purchase plant, machinery and equipment for its manufacturing facilities in Goa and Visakhapatnam, while the remaining proceeds will be used for general corporate purposes.
The Molbio Diagnostics Management present at the IPO were Sriram Natarajan, Executive Director and Chief Executive Office; Dr. Chandrasekhar Bhaskaran Nair, Executive Director and Chief Technology Officer; Manan Bimal Khokhani, President Finance and Accounts and Chief Financial Officer; Shiva Sriram, President, Business Development and Indraneil Borkakoty, President – Corporate Strategy, Mergers and Acquisitions and Investor Relations
Molbio Diagnostics reported strong financial performance in FY26, with net profit rising 14.8% to ₹166.6 crore, while revenue increased 41.7% to ₹1,445.7 crore.Kotak Mahindra Capital Company, IIFL Capital Services and Jefferies India are the book-running lead managers to the issue.
The basis of allotment is expected to be finalised on August 13, with the company’s shares likely to list on the stock exchanges on August 17.
About Molbio Diagnostics : We are an innovative point-of-care (“POC”) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. We have developed our ‘Truenat’ platform, which is a novel POC polymerase chain reaction (“PCR”) platform that can operate in resource limited settings since its battery operated, facilitating decentralized diagnosis within an hour.
As of March 31, 2026, Truenat is patented in more than 100 countries for the diagnosis of multiple infectious and non-communicable diseases. As of March 31, 2026, we offer molecular testing for 30 diseases, including
tuberculosis (“TB”), COVID, Hepatitis B and C, Human immunodeficiency virus (“HIV”), and Human Papillomavirus (“HPV”) with 43 assays. We operate in an oligopolistic market with high entry barriers, evidenced by the fact that our platform underwent 13 years of R&D to obtain Indian Council of Medical Research (“ICMR”) certification and our ‘Truenat’ test chip for diagnosing TB is the only one by an Indian company and one of the only two rapid molecular tests in the world, which has been endorsed by the World Health Organization (“WHO”) for initial diagnosis of TB and rifampicin resistance detection using molecular diagnostic technology. (Source: 1Lattice Report). We also provide devices, enabling radiology, digital pathology and breast health screening, through our Subsidiaries, Prognosys and OptraScan and collaboration partner – UE Lifesciences. Further, we are focussed towards building a pipeline of additional products and platforms that are currently at various stages of development.
